The Trump administration’s decision to withdraw from the World Health Organization could complicate US access to health information that’s vital for pharmaceutical companies, academics said
Meena Seshamani believes the landmark Inflation Reduction Act will “lay the foundation” for future drug price negotiations under the new Trump administration. Seshamani, the former
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
HHS told the Second Circuit that Boehringer Ingelheim’s voluntary participation in Medicare negotiations “undermines” its legal challenge to the process. Voluntariness was a key factor
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report. The company’s estimates have varied
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS